Showing results (31-40 of 715) with videos related to
Sort By:
Pageof 72
International Journal of Hematology|June 8, 2006
New strategies in chronic myeloid leukemiaHagop M Kantarjian, Jorge CortesFuture Oncology (London, England)|October 17, 2008
Nilotinib: a phenylamino-pyrimidine derivative with activity against BCR-ABL, KIT and PDGFR kinasesAlfonso Quintás-Cardama, Jorge CortesExpert Opinion on Drug Delivery|December 26, 2014
Liposomal delivery of nucleic acid-based anticancer therapeutics: BP-100-1.01Ana Tari Ashizawa, Jorge CortesOncology (Williston Park, N.Y.)|May 14, 2008
Management of patients with resistant or refractory chronic myelogenous leukemiaAlfonso Quintás-Cardama, Jorge CortesLeukemia Research|February 5, 2008
Tailoring tyrosine kinase inhibitor therapy to tackle specific BCR-ABL1 mutant clonesAlfonso Quintás-Cardama, Jorge CortesClinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 17, 2008
Therapeutic options against BCR-ABL1 T315I-positive chronic myelogenous leukemiaAlfonso Quintás-Cardama, Jorge CortesBlood|October 2, 2008
Molecular biology of bcr-abl1-positive chronic myeloid leukemiaAlfonso Quintás-Cardama, Jorge CortesExpert Opinion on Investigational Drugs|March 21, 2007
Evaluation of the L-stereoisomeric nucleoside analog troxacitabine for the treatment of acute myeloid leukemiaAlfonso Quintás-Cardama, Jorge CortesIdrugs : the Investigational Drugs Journal|May 10, 2008
Omacetaxine mepesuccinate--a semisynthetic formulation of the natural antitumoral alkaloid homoharringtonine, for chronic myelocytic leukemia and other myeloid malignanciesAlfonso Quintás-Cardama, Jorge CortesCurrent Oncology Reports|June 14, 2021
Review of New-Generation Tyrosine Kinase Inhibitors for Chronic Myeloid LeukemiaMahran Shoukier, Michal Kubiak, Jorge CortesPageof 72